AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03840447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management programme
Description: The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens.
Study NCT02215967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Description: 0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
Study NCT03580473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SATURNO II association
Description: opthalmic solution, 4 times a day
Study NCT03580473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigadexa®
Description: opthalmic solution, 4 times a day
Study NCT00321178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR4 - switch to CR4
Description: switch to oral treatment after 4 weeks SR 'standard' therapy
Study NCT00321178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR4 - switch to CR4
Description: switch to oral treatment after 4 weeks SR 'standard' therapy
Study NCT02977819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation practice
Description: 18 months
Study NCT02977819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning English as a foreign language
Description: 18 months
Study NCT03170128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises in addition to standard follow-up visits
Description: Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
Study NCT02940288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
Study NCT02940288 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
Study NCT05294666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
Study NCT01867827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback and Physical Exercise
Study NCT01867827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Study NCT02591355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
Study NCT02591355 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution injection
Description: Placebo is a saline solution
Study NCT00070187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00070187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study NCT00070187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00070187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00017147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm.
Study NCT00017147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm.
Study NCT00017147 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
Study NCT00017147 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
Study NCT00017147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: 120 mg/m\^2 IV over 1 hour on day 1 of each cycle
Study NCT01761214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluroquinolones
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
Study NCT01761214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-lactamase inhibitor
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
Study NCT02278107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tidal Assist Ventilator System
Description: Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
Study NCT02278107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula Oxygen
Description: Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
Study NCT00003901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00003901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study NCT00003901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT05196841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anastatica Hierochuntica
Description: During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
Study NCT02503332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Study NCT02503332 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study NCT00520975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study NCT00520975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT04572074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guided imagery
Description: 10 minutes of guided imagery experience
Study NCT04572074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 10 minutes of virtual reality experience
Study NCT04426682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urodynamics parameters
Description: Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure.
Study NCT03999190 — intervention group
Intervention type: DRUG
Intervention: NPA radiotracer
Description: \[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
Study NCT03999190 — intervention group
Intervention type: DRUG
Intervention: Raclopride radiotracer
Description: \[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
Study NCT03999190 — intervention group
Intervention type: DRUG
Intervention: Dextroamphetamine
Description: Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
Study NCT00555607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisolone
Description: Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
Study NCT00555607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
Study NCT01895660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.
Study NCT01895660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation
Description: Types of constraint and dosage amounts will be varied.
Study NCT02174068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os
Study NCT01524848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: Two (2) tablets of 400 mg given once daily continuously
Study NCT03103945 — intervention group
Intervention type: DEVICE
Intervention: CDS box connection of the Niobe™ Remote Magnetic Navigation System
Description: For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
Study NCT01430299 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Demineralized Bone Matrix
Description: Accell Evo3 in posteriolateral fusion (prospective cohort)
Study NCT01430299 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: rh-BMP2
Description: rh-BMP2 in posterolateral fusion (retrospective cohort)
Study NCT00895076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: iontophoretic patch and injection
Study NCT00895076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: iontophoretic patch and injection
Study NCT02966197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic internal iliac artery balloon catheterization
Description: Between June 2015 and August 2016
Study NCT02966197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic internal iliac artery balloon
Study NCT02966197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiology operation
Study NCT05294666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
Study NCT02891668 — intervention group
Intervention type: DRUG
Intervention: Levothyroxine treatment
Description: Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
Study NCT00134901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine
Study NCT00134901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01630070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expandable drug eluting stent
Description: Self-Expanding Paclitaxel-Eluting stent
Study NCT03170063 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure/Surgery: Biofluid samplings
Description: Biofluid samplings (blood and cerebrospinal fluid (CSF))
Study NCT02125864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal injection
Description: collecting blood samples
Study NCT02624180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
Study NCT02624180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance containing no medication
Study NCT04735978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified HSV-1
Study NCT04167852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily text message
Description: Patients will receive a daily text message stating how many days they have until or since their surgery.
Study NCT04735978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD1 monoclonal antibody
Study NCT00753311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rizatriptan or placebo
Description: Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
Study NCT00753311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rizatriptan or placebo
Description: Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
Study NCT03169231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Intravenously delivered
Study NCT04167852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Patients will receive a link to mindfulness meditation intervention for ten minutes.
Study NCT03401099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of CTI
Description: Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
Study NCT03401099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon PVI
Description: Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
Study NCT01945086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
Study NCT01945086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injections of placebo at Week 0 and Week 4.
Study NCT01945086 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Concomitant topical medications for atopic dermatitis
Description: Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
Study NCT01945086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant topical medications for atopic dermatitis
Description: Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
Study NCT01381198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal rectus femoris transfer
Description: Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
Study NCT04472715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: follicular unit extarcation and platelet rich plasma
Description: hair transplantation procedure
Study NCT00295932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT03948919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota
Description: Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
Study NCT03948919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
Study NCT00996060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and Valproic Acid: Cohort -1
Description: Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day.
Study NCT01653392 — intervention group
Intervention type: BIOLOGICAL
Intervention: Observational Intervention
Description: This is an observational study, therefore no interventions are specified.
Study NCT00943371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6349
Description: Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
Study NCT00943371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MK6349
Description: Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods